Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Accumulated Expenses (2020 - 2025)

Inmune Bio's Other Accumulated Expenses history spans 6 years, with the latest figure at $511000.0 for Q2 2025.

  • For Q2 2025, Other Accumulated Expenses fell 1.92% year-over-year to $511000.0; the TTM value through Jun 2025 reached $511000.0, down 1.92%, while the annual FY2024 figure was $517000.0, 5.73% up from the prior year.
  • Other Accumulated Expenses for Q2 2025 was $511000.0 at Inmune Bio, up from $480000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $778000.0 in Q3 2022 and bottomed at $474000.0 in Q4 2021.
  • The 5-year median for Other Accumulated Expenses is $531000.0 (2021), against an average of $548722.2.
  • The largest annual shift saw Other Accumulated Expenses soared 149.47% in 2021 before it plummeted 36.25% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $474000.0 in 2021, then grew by 29.96% to $616000.0 in 2022, then dropped by 20.62% to $489000.0 in 2023, then grew by 5.73% to $517000.0 in 2024, then dropped by 1.16% to $511000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Other Accumulated Expenses are $511000.0 (Q2 2025), $480000.0 (Q1 2025), and $517000.0 (Q4 2024).